- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy of hepatocellular carcinoma: Present and future
Authors
Keywords
-
Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 27, Issue 5, Pages 862-872
Publisher
Wiley
Online
2012-02-27
DOI
10.1111/j.1440-1746.2012.07096.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).
- (2017) A. X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).
- (2017) A. Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
- (2011) Stephen L. Chan et al. CANCER
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
- (2011) Andrew X. Zhu et al. CANCER
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
- (2011) T. Yau et al. CLINICAL CANCER RESEARCH
- 6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma – a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG)
- (2011) W. Yeo et al. EUROPEAN JOURNAL OF CANCER
- 6576 POSTER Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma
- (2011) L. Bolondi et al. EUROPEAN JOURNAL OF CANCER
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Molecular classification of hepatocellular carcinoma anno 2011
- (2011) H. van Malenstein et al. EUROPEAN JOURNAL OF CANCER
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
- (2011) Hanning You et al. HEPATOLOGY
- TACE and Sorafenib: A Good Marriage?
- (2011) Ghassan K. Abou-Alfa JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
- (2011) Timothy M. Pawlik et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
- (2011) Bert H. O'Neil et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting insulin-like growth factor axis in hepatocellular carcinoma
- (2011) Jennifer Wu et al. Journal of Hematology & Oncology
- Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
- (2011) Wei-Tien Tai et al. JOURNAL OF HEPATOLOGY
- Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
- (2011) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia
- (2011) Whitney Miller et al. LANCET ONCOLOGY
- Cancer epigenetics reaches mainstream oncology
- (2011) Manuel Rodríguez-Paredes et al. NATURE MEDICINE
- HCC and angiogenesis: possible targets and future directions
- (2011) Andrew X. Zhu et al. Nature Reviews Clinical Oncology
- Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
- (2011) A. A. Adjei et al. ONCOLOGIST
- Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
- (2010) C-H Hsu et al. BRITISH JOURNAL OF CANCER
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
- (2010) Fumihiko Kanai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
- (2010) E. Martinelli et al. CLINICAL CANCER RESEARCH
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population
- (2010) Stephen L Chan et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis
- (2010) Tae-Hee Um et al. JOURNAL OF HEPATOLOGY
- O2 regulates stem cells through Wnt/β-catenin signalling
- (2010) Jolly Mazumdar et al. NATURE CELL BIOLOGY
- Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
- (2010) Curtis A Thorne et al. Nature Chemical Biology
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study
- (2010) J.-F. Dufour et al. ONCOLOGIST
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
- (2009) T. Bekaii-Saab et al. CLINICAL CANCER RESEARCH
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation
- (2009) Daniela Carlisi et al. EUROPEAN JOURNAL OF CANCER
- The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
- (2009) Brigette B.Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
- (2009) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
- (2009) Ledu Zhou et al. MEDICAL ONCOLOGY
- Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
- (2009) Shih-Min A. Huang et al. NATURE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization
- (2008) B. Wang et al. ACTA RADIOLOGICA
- Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness
- (2008) Adriana Sergio et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More